Brokerages forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will report $104.45 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for NxStage Medical’s earnings, with the highest sales estimate coming in at $104.59 million and the lowest estimate coming in at $104.30 million. NxStage Medical reported sales of $93.01 million during the same quarter last year, which indicates a positive year-over-year growth rate of 12.3%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that NxStage Medical will report full year sales of $104.45 million for the current fiscal year, with estimates ranging from $394.93 million to $398.30 million. For the next fiscal year, analysts anticipate that the company will post sales of $436.18 million per share, with estimates ranging from $435.90 million to $436.45 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover NxStage Medical.
Several equities research analysts recently issued reports on NXTM shares. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Northland Securities reissued a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research report on Wednesday, November 8th. ValuEngine lowered NxStage Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised NxStage Medical from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Three analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $30.25.
A number of hedge funds and other institutional investors have recently modified their holdings of NXTM. Public Employees Retirement Association of Colorado acquired a new stake in NxStage Medical in the fourth quarter worth $128,000. Prudential Financial Inc. acquired a new stake in NxStage Medical in the third quarter worth $202,000. Amalgamated Bank increased its position in NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after buying an additional 553 shares during the period. Koch Industries Inc. acquired a new stake in NxStage Medical in the second quarter worth $227,000. Finally, Suntrust Banks Inc. increased its position in NxStage Medical by 2.3% in the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after buying an additional 209 shares during the period. 84.37% of the stock is currently owned by hedge funds and other institutional investors.
NxStage Medical (NASDAQ NXTM) traded up $1.15 during trading on Tuesday, hitting $24.62. The stock had a trading volume of 728,620 shares, compared to its average volume of 625,414. The stock has a market cap of $1,630.63, a PE ratio of -351.71 and a beta of -0.08. NxStage Medical has a 12 month low of $20.45 and a 12 month high of $30.80.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.